CAR-T Safe, Active in Hodgkin Lymphoma

(MedPage Today) -- A majority of patients with relapsed/refractory Hodgkin lymphoma responded to CD30-targeted chimeric antigen receptor (CAR) T-cell therapy, which caused no significant toxicity, a preliminary clinical study showed.
Overall...